Guidelines for management of infectious complications after chimeric antigen receptor T cell therapy and bispecific antibodies for haematological malignancies
Key facts
Chair(s): Maddalena Giannella, Italy
Approval date: February 2026
Expected completion: August 2026
Last status report date: February 2026
Status Report
Guideline Development Steps
Status
Guideline Group Membership
Completed
Establishing Guideline Group Processes
Completed
Identifying Target Audience and Topic Selection
Completed
Consumer and Stakeholder Involvement
Completed
Conflict of Interest Considerations
Completed
(PICO) Question Generation
Ongoing
Considering Importance of Outcomes and Interventions, Values, Preferences and Utilities
Not started
Literature Searches
Not started
Screening of Literature
Not started
Data Extraction
Not started
Risk of Bias Assessment
Not started
Summarising Evidence
Not started
Judging Quality, Strength or Certainty of a Body of Evidence (GRADE)
Not started
Developing Recommendations and Determining their Strength (EtDs)
Not started
Wording of Recommendations and Considerations of Implementation, Feasibility and Equity
